Part 3 of 4:Â
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss.Â
Join us this week to hear about:- Neela’s transition from Genentech to Poniard Pharmaceuticals
- Her collaboration with Greg Hageman on age-related macular degeneration
- Raising $37 million in Series A financing
- Neela’s role at Poniard developing pipeline strategy with the head of chemistry
- Her experiences at Abbott and AbbVie as Director of Global External Research and Search & Evaluation, respectively.
Please enjoy Jon’s conversation with Neela Patel!
Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Find Our Guest, Neela Patel, at these links:Â https://www.linkedin.com/in/neela-patel-84b144/Â https://bonumtx.com/Â
Find Our Host, Jon Chee, at these links:Â https://www.linkedin.com/in/joncheehttps://www.excedr.com
Excedr Socials & WebsiteLinkedIn: https://www.linkedin.com/company/excedr/ Youtube: https://www.youtube.com/@excedr Instagram: https://www.instagram.com/excedr_inc Twitter: https://twitter.com/ExcedrInc Facebook: https://www.facebook.com/excedr TikTok: https://www.tiktok.com/@excedr Podcast Website: https://www.thebiotechstartupspodcast.com/Â
Enriched Notes:Â
Topics Mentioned:Genentech: https://www.gene.com/Poniard Pharmaceuticals: https://www.linkedin.com/company/poniard-pharmaceuticals/Abbott: https://www.abbott.com/AbbVie: https://www.abbvie.com/Seattle Genetics (Pfizer): https://www.seagen.com/who-we-are/historyPatents Licensing in Biotech: https://www.excedr.com/resources/how-patent-licensing-worksIP Strategy for Biotechs: https://www.excedr.com/resources/intellectual-property-strategy-for-biotechsPartnering with Big Pharma: https://www.excedr.com/blog/how-biotech-partnerships-support-researchAntibody Drug Conjugates (Prime Antibody): https://www.excedr.com/resources/primary-antibodyCorporate Development: https://corporatefinanceinstitute.com/resources/management/corporate-development-guide/In Licensing and Out Licensing: https://www.excedr.com/blog/life-sciences-licensing-agreements-guideBootstrapping Your Biotech: https://www.excedr.com/resources/how-to-bootstrap-biotech-startup
People Mentioned:Greg Hageman: https://medicine.utah.edu/faculty/gregory-s-hagemanSteve Dedinson: https://www.linkedin.com/in/steve-davidsen-0a65414/Â Saul Rosenberg: https://www.linkedin.com/in/saul-rosenberg-638a6910/
Timestamps:00:28 Intro01:50 Starting a company after Genentech experience02:36 Greg Hageman’s key gene discovery and securing Series A funding05:32 Developing pipeline strategy at Poniard06:43 Transitioning to BD (Search and Evaluation) at Abbott12:31 Spinning out AbbVie, Neela’s continued focus on Oncology14:58 Fostering innovation and external ideas at AbbVie16:51 Evaluating small companies & the biggest challenge of Search and Evaluation20:13 Key factors for startups looking to partner with big pharma26:32 Transitioning to Seattle Genetics (Seagen) and Corporate Development29:28 Neela’s CorpDev experience, navigating unique challenges34:03 Understanding how to diversify revenue streams and navigate cycles39:01 OutroThe Biotech Startups Podcast gives you a front-row seat to the business
and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.
View all episodes
